Literature DB >> 2464391

Effects of charybdotoxin, a blocker of Ca2+-activated K+ channels, on motor nerve terminals.

A J Anderson1, A L Harvey, E G Rowan, P N Strong.   

Abstract

1. The contribution of Ca2+-activated K+ currents (IK,Ca) to the control of electrical excitability of motor nerve terminals and the control of acetylcholine release was assessed by studying the effects of the specific K(Ca) channel blocking toxins charybdotoxin and apamin. Electrical activity of the terminal regions of motor nerves was assessed by extracellular recording from an electrode placed in the perineural sheaths of nerves in the mouse triangularis sterni and frog cutaneous pectoris preparations. Acetylcholine release was monitored by intracellular recording of endplate potentials (e.p.ps). 2. Charybdotoxin (20-300 nM), but not apamin (10 nM-2.5 microM), selectively reduced the amplitude of an IK,Ca unmasked by prior blockade of the delayed rectifier K+ current with 3,4-diaminopyridine (3,4-DAP). 3. In the combined presence of 3,4-DAP and charybdotoxin, large Ca2+-dependent plateau responses developed, but only moderate and transient increases in acetylcholine release occurred. 4. In the absence of 3,4-DAP, charybdotoxin did not alter the electrical activity of, or the transmitter release from motor nerve terminals. 5. A possible role of the charybdotoxin-sensitive IK,Ca in the control of transmitter release is discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2464391      PMCID: PMC1854283          DOI: 10.1111/j.1476-5381.1988.tb11772.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  31 in total

1.  The peptide components of bee venom.

Authors:  J Gauldie; J M Hanson; F D Rumjanek; R A Shipolini; C A Vernon
Journal:  Eur J Biochem       Date:  1976-01-15

2.  Effects of apamin, quinine and neuromuscular blockers on calcium-activated potassium channels in guinea-pig hepatocytes.

Authors:  N S Cook; D G Haylett
Journal:  J Physiol       Date:  1985-01       Impact factor: 5.182

3.  Charybdotoxin, a protein inhibitor of single Ca2+-activated K+ channels from mammalian skeletal muscle.

Authors:  C Miller; E Moczydlowski; R Latorre; M Phillips
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

4.  The antagonism between botulinum toxin and calcium in motor nerve terminals.

Authors:  C B Gundersen; B Katz; R Miledi
Journal:  Proc R Soc Lond B Biol Sci       Date:  1982-10-22

5.  Presynaptic currents in frog motor endings.

Authors:  A Mallart
Journal:  Pflugers Arch       Date:  1984-01       Impact factor: 3.657

6.  Presynaptic currents in mouse motor endings.

Authors:  J L Brigant; A Mallart
Journal:  J Physiol       Date:  1982-12       Impact factor: 5.182

7.  Advantages of the triangularis sterni muscle of the mouse for investigations of synaptic phenomena.

Authors:  J J McArdle; D Angaut-Petit; A Mallart; R Bournaud; L Faille; J L Brigant
Journal:  J Neurosci Methods       Date:  1981-08       Impact factor: 2.390

8.  The action of calcium on neuronal synapses in the squid.

Authors:  R Miledi; C R Slater
Journal:  J Physiol       Date:  1966-05       Impact factor: 5.182

9.  The coexistence in rat muscle cells of two distinct classes of Ca2+-dependent K+ channels with different pharmacological properties and different physiological functions.

Authors:  G Romey; M Lazdunski
Journal:  Biochem Biophys Res Commun       Date:  1984-01-30       Impact factor: 3.575

10.  Charybdotoxin block of single Ca2+-activated K+ channels. Effects of channel gating, voltage, and ionic strength.

Authors:  C S Anderson; R MacKinnon; C Smith; C Miller
Journal:  J Gen Physiol       Date:  1988-03       Impact factor: 4.086

View more
  25 in total

1.  On the blockade of acetylcholine release at mouse motor nerve terminals by beta-bungarotoxin and crotoxin.

Authors:  E G Rowan; K E Pemberton; A L Harvey
Journal:  Br J Pharmacol       Date:  1990-06       Impact factor: 8.739

2.  Effects of tacrine, velnacrine (HP029), suronacrine (HP128), and 3,4-diaminopyridine on skeletal neuromuscular transmission in vitro.

Authors:  M F Braga; A L Harvey; E G Rowan
Journal:  Br J Pharmacol       Date:  1991-04       Impact factor: 8.739

3.  Modulation of calcium currents is eliminated after cleavage of a strategic component of the mammalian secretory apparatus.

Authors:  Eugene M Silinsky
Journal:  J Physiol       Date:  2005-06-16       Impact factor: 5.182

4.  Effects of brevetoxin-B on motor nerve terminals of mouse skeletal muscle.

Authors:  M C Tsai; M L Chen
Journal:  Br J Pharmacol       Date:  1991-05       Impact factor: 8.739

5.  Selective disruption of the mammalian secretory apparatus enhances or eliminates calcium current modulation in nerve endings.

Authors:  Eugene M Silinsky
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-17       Impact factor: 11.205

6.  Activity-dependent modulation of the presynaptic potassium current in the frog neuromuscular junction.

Authors:  F Miralles; C Solsona
Journal:  J Physiol       Date:  1996-09-15       Impact factor: 5.182

7.  Effects of Ca2+ channel blockers on transmitter release and presynaptic currents at the frog neuromuscular junction.

Authors:  E Katz; P A Ferro; B D Cherksey; M Sugimori; R Llinás; O D Uchitel
Journal:  J Physiol       Date:  1995-08-01       Impact factor: 5.182

8.  Modulation of acetylcholine release at mouse neuromuscular junctions by interaction of three homologous scorpion toxins with K+ channels.

Authors:  H Vatanpour; A L Harvey
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

9.  Transmitter-mediated local contracture of the endplate region of the focally innervated mouse diaphragm treated with anticholinesterase.

Authors:  S J Hong; C C Chang
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

10.  Reversal by cysteine of the cadmium-induced block of skeletal neuromuscular transmission in vitro.

Authors:  M F Braga; E G Rowan
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.